Old Web
English
Sign In
Acemap
>
authorDetail
>
Fabienne Staelens
Fabienne Staelens
UCB
Medicine
Internal medicine
moderate to severe
plaque psoriasis
Bimekizumab
4
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
27383 Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
2021
Journal of The American Academy of Dermatology
Andrew Blauvelt
Yayoi Tada
Lars Iversen
Ulrich Mrowietz
Mark Lebwohl
Maggie Wang
Veerle Vanvoorden
Eva Cullen
Fabienne Staelens
Kim A. Papp
Show All
Source
Cite
Save
Citations (0)
Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
2021
Andrew Blauvelt
Lars Iversen
Sandy McBride
Melinda Gooderham
Petra Staubach
Paul S. Yamauchi
Fabienne Staelens
Veerle Vanoorden
Katy White
Paolo Gisondi
Show All
Source
Cite
Save
Citations (0)
Maintien de la réponse par bimékizumab jusqu’à 1 an chez des patients présentant un psoriasis en plaques modéré à sévère : résultats groupés de trois études de phase 3
2021
Maria-Polina Konstantinou
Andrew Blauvelt
Yayoi Tada
Lars Iversen
Ulrich Mrowietz
Mark Lebwohl
Maggie Wang
Veerle Vanvoorden
Eva Cullen
Fabienne Staelens
Kim Papp
Show All
Source
Cite
Save
Citations (0)
Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study
2019
Therapeutic Advances in Musculoskeletal Disease
Louis Bessette
Boulos Haraoui
Andrew Chow
I. Fortin
S. Dixit
Majed Khraishi
Derek Haaland
Sami Elmoufti
Fabienne Staelens
Irina Bogatyreva
Jerry Syrotuik
S. Shaikh
Show All
Source
Cite
Save
Citations (1)
1